Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Translationally Controlled Tumour Protein (TCTP): a novel therapeutic target for the treatment of Pulmonary Arterial Hypertension

FY 2013-14

Summary
Pulmonary arterial hypertension (PAH) is a devastating disease characterized by elevated pulmonary arterial pressures, increased vascular resistance, and a poor prognosis due to right heart failure. In healthy individuals, the pulmonary arteries carry deoxygenated blood from the right side of the heart to the lungs to be re-oxygenated. After passing through the lungs, the now oxygenated blood is returned to the heart by the pulmonary veins and distributed to the rest of the body via the systemic circulation. In patients with PAH, the cells lining the inside of the pulmonary arteries, known as endothelial cells (ECs), become damaged leading to uncontrolled growth and the formation of complex vascular lesions. These damaged ECs contribute to blood vessel remodeling which obstructs the flow of blood through the small pulmonary arteries, the same way rust buildup prevents flow through the inside of a pipe. This blockage of blood flow forces the heart to work harder in order to deliver an adequate volume of blood to the lungs for re-oxygenation and distribution throughout the body. Over time this increased workload can cause the heart to fail. While there are a number of therapies for PAH that target the endothelium by inducing vasodilatation (i.e. blood vessel relaxation), there are no current therapies that specifically target the unregulated EC growth that contributes to occlusive remodeling. Genetic evidence indicates that 60% of patients with hereditary PAH (HPAH), and approximately a quarter of patients with sporadic PAH, harbour “loss-of-function” mutations in the gene encoding for Bone Morphogenetic Protein Receptor 2 (BMPR2). In order to study how BMPR2 mutations may predispose pulmonary artery ECs to subsequent damage and dysfunction, our lab has developed methodology to isolate circulating blood-outgrowth endothelial cells (BOECs) from the peripheral circulation of PAH patients with known BMPR2 mutations and compare them to BOECs from healthy individuals. BOECs share a number of similarities with lung ECs and provide a safe alternative to isolating ECs directly from the lungs of PAH patients. Thus, these “patient-specific” cells are the ideal platform to study the effects of BMPR2 mutations on EC biology. Utilizing a thorough “proteomic” screening approach to compare protein levels in BOECs from HPAH and healthy control patients, our lab indentified Translationally Controlled Tumour Protein (TCTP) to be one of twenty-two significantly dysregulated proteins in the unhealthy cells. In our preliminary studies, immunofluorescence (glow in the dark) staining for TCTP in HPAH patient lung sections showed increased expression and localization of TCPT in ECs within vascular lesions. Decreasing the level of TCTP in BOECs isolated from HPAH patients using small interfering RNAs resulted in a marked reduction in growth and sensitized the cells to normal triggers of cell death. TCTP expression was also markedly increased in the remodeled arterioles in the SU5416 experimental rat model of PAH. These preliminary data identified TCTP as a potential mediator of dysregulated EC growth and subsequent vascular lesion formation in PAH. The proposed research projects described in this application will further assess the role of TCTP in the development of PAH by increasing TCTP (i.e. over expression) and alternatively by decreasing TCTP (i.e. knockdown) in the SU5416 rat model of PAH. Furthermore, the efficacy of two commercially available pharmaceuticals found to selectively target and inhibit TCTP will be tested in the SU5416 rat model of PAH as potential therapies. Collectively, these proposed experiments will greatly improve our understanding of PAH development while simultaneously exploring clinically relevant treatments.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
311697
Name
Foster William S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Translationally Controlled Tumour Protein (TCTP): a novel therapeutic target for the treatment of Pulmonary Arterial Hypertension
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cell Biology/Structural Biology; Pulmonary Arterial Hypertension; Pulmonary Circulation And Disease; Translationally Controlled Tumour Protein; Vascular Endothelium
Abstract
Pulmonary arterial hypertension (PAH) is a devastating disease characterized by elevated pulmonary arterial pressures, increased vascular resistance, and a poor prognosis due to right heart failure. In healthy individuals, the pulmonary arteries carry deoxygenated blood from the right side of the heart to the lungs to be re-oxygenated. After passing through the lungs, the now oxygenated blood is returned to the heart by the pulmonary veins and distributed to the rest of the body via the systemic circulation. In patients with PAH, the cells lining the inside of the pulmonary arteries, known as endothelial cells (ECs), become damaged leading to uncontrolled growth and the formation of complex vascular lesions. These damaged ECs contribute to blood vessel remodeling which obstructs the flow of blood through the small pulmonary arteries, the same way rust buildup prevents flow through the inside of a pipe. This blockage of blood flow forces the heart to work harder in order to deliver an adequate volume of blood to the lungs for re-oxygenation and distribution throughout the body. Over time this increased workload can cause the heart to fail. While there are a number of therapies for PAH that target the endothelium by inducing vasodilatation (i.e. blood vessel relaxation), there are no current therapies that specifically target the unregulated EC growth that contributes to occlusive remodeling. Genetic evidence indicates that 60% of patients with hereditary PAH (HPAH), and approximately a quarter of patients with sporadic PAH, harbour “loss-of-function” mutations in the gene encoding for Bone Morphogenetic Protein Receptor 2 (BMPR2). In order to study how BMPR2 mutations may predispose pulmonary artery ECs to subsequent damage and dysfunction, our lab has developed methodology to isolate circulating blood-outgrowth endothelial cells (BOECs) from the peripheral circulation of PAH patients with known BMPR2 mutations and compare them to BOECs from healthy individuals. BOECs share a number of similarities with lung ECs and provide a safe alternative to isolating ECs directly from the lungs of PAH patients. Thus, these “patient-specific” cells are the ideal platform to study the effects of BMPR2 mutations on EC biology. Utilizing a thorough “proteomic” screening approach to compare protein levels in BOECs from HPAH and healthy control patients, our lab indentified Translationally Controlled Tumour Protein (TCTP) to be one of twenty-two significantly dysregulated proteins in the unhealthy cells. In our preliminary studies, immunofluorescence (glow in the dark) staining for TCTP in HPAH patient lung sections showed increased expression and localization of TCPT in ECs within vascular lesions. Decreasing the level of TCTP in BOECs isolated from HPAH patients using small interfering RNAs resulted in a marked reduction in growth and sensitized the cells to normal triggers of cell death. TCTP expression was also markedly increased in the remodeled arterioles in the SU5416 experimental rat model of PAH. These preliminary data identified TCTP as a potential mediator of dysregulated EC growth and subsequent vascular lesion formation in PAH. The proposed research projects described in this application will further assess the role of TCTP in the development of PAH by increasing TCTP (i.e. over expression) and alternatively by decreasing TCTP (i.e. knockdown) in the SU5416 rat model of PAH. Furthermore, the efficacy of two commercially available pharmaceuticals found to selectively target and inhibit TCTP will be tested in the SU5416 rat model of PAH as potential therapies. Collectively, these proposed experiments will greatly improve our understanding of PAH development while simultaneously exploring clinically relevant treatments.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Foster, William S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~